Answers are grounded in this paper and cite their sources.
Background Atherosclerosis (AS) is a chronic inflammatory disease underpinning major cardiovascular events. Neutrophil extracellular traps (NETs) contribute to AS progression, but whether antiplatelet therapy with indobufen affects NETs remains unknown. This study investigates the effects and mechanisms of indobufen and a novel PAD4 inhibitor on NET formation and AS pathogenesis. Methods Circulating NETs markers were quantified in patients with coronary heart disease. In vitro, we assessed the impact of NETs on endothelial cell apoptosis and signaling, and examined the role of activated platelets in inducing NETosis. An AS mouse model was used to evaluate the therapeutic effects of indobufen and the PAD4 inhibitor HH9429, alone or in combination, on plaque burden and NET-related mechanisms. Results NET levels were elevated in patients with CHD. NETs directly induced endothelial apoptosis via the JAK2-STAT3 pathway. Mechanistically, activated platelets triggered NET release through HMGB1, a process significantly attenuated by indobufen. In vivo, both indobufen and HH9429 reduced NET formation and atherosclerotic lesions, and their combination produced enhanced therapeutic effects by suppressing the HMGB1-RAGE axis and NET-associated inflammation. Conclusions Indobufen limits NETs formation by inhibiting platelet-derived HMGB1. Combining indobufen with a PAD4 inhibitor amplifies these protective effects, highlighting a potential dual-target strategy against NET-mediated pathology in AS. These findings provide new insights into platelet-NET crosstalk and suggest a promising therapeutic approach.
No takes yet. Share an insight, caveat, or question.
Zhao et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: